

**Blue Cross Blue Shield Arizona**  
**Medical Drug Management Code List**

**\*\*\*Please note: This list is constantly evolving as new drugs come to market and are approved by the FDA as well as with any HCPC code changes issued by CMS. Please contact Blue Cross Blue Shield Arizona or EviCore, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed\*\*\***

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
AbobotulinumtoxinA	Dysport	J0586	Medical Drug Management	Neuromusclar Drugs	Y	
Adacatumab-avwa	Aduhelm	J0172	Medical Drug Management	Misc Psychotherapeutic and Neurological Agents	Y	
ADAMTS13, Recombinant-krhn	Adzynma	C9399	Medical Drug Management	Congenital thrombotic thrombocytopenic purpura	Y	C9167 will replace C9399 for Adzynma, effective: 04/01/24
ADAMTS13, Recombinant-krhn	Adzynma	C9167	Medical Drug Management	Congenital thrombotic thrombocytopenic purpura	Y	C9167 will replace C9399 for Adzynma, effective: 04/01/24
ADAMTS13, Recombinant-krhn	Adzynma	J3590	Medical Drug Management	Congenital thrombotic thrombocytopenic purpura	Y	
Afamelanotide	Scenesse	J7352	Medical Drug Management	Topical Products	Y	
Aflibercept	Eylea	J0178	Medical Drug Management	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Agalsidase Beta	Fabrazyme	J0180	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Alemtuzumab	Lemtrada	J0202	Medical Drug Management	Psychotherapeutic and Neurological Agents	Y	
Alglucosidase Alfa	Lumizyme	J0221	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Alpha1-proteinase inhibitors	Aralast NP, Prolastin-C, Zemaira	J0256	Medical Drug Management	Respiratory Agents	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Alpha1-proteinase inhibitors	Glassia	J0257	Medical Drug Managment	Respiratory Agents	Y	
Altuviio	Hemophilia clotting factor, not otherwise classified	J7199	Medical Drug Managment	Hematological Agents	Y	
Anifrolumab-fnia	Saphnelo	J0491	Medical Drug Managment	Miscellaneous Products	Y	
Anti-inhibitor	Feiba	J7198	Medical Drug Managment	Hematological Agents	Y	
Antihemophilic Factor (Recombinant)	Obizur	J7188	Medical Drug Managment	Hematological Agents	Y	
Antihemophilic factor (recombinant). glycopegylated-exei	Esperoct	J7204	Medical Drug Managment	Hematological Agents	Y	
Apomorphine	Apokyn	J0364	Medical Drug Managment	Neuromusclar Drugs	Y	
Avacincaptad pegol	Izervay	J2782	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	New permanent HCPC Code: J2782 will replace NOC Codes: C9162 & J3490 for Izervay, effective: 04/01/24
Avacincaptad pegol	Izervay	C9162	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	New permanent HCPC Code: J2782 will replace NOC Codes: C9162 & J3490 for Izervay, effective: 04/01/24
Avacincaptad pegol	Izervay	J3490	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	New permanent HCPC Code: J2782 will replace NOC Codes: C9162 & J3490 for Izervay, effective: 04/01/24
Avalglucosidase alfa-ngpt	Nexviazyme	J0219	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Benralizumab	Fasenra	J0517	Medical Drug Managment	Respiratory Agents	Y	
Bevacizumab	Avastin	C9257	Medical Drug Managment	Antineoplastic Agents and Adjunctive Therapies	Y	
Bevacizumab	Avastin	J9035	Medical Drug Managment	Antineoplastic Agents and Adjunctive Therapies	Y	
Bezlotoxumab	Zinplava	J0565	Medical Drug Managment	Biologicals	Y	
Bimatoprost Intracameral implant	Durysta	J7351	Medical Drug Managment	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Brexanolone	Zulresso	J1632	Medical Drug Managment	Central Nervous Systems Drugs	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Brolucizumab-dbl	Beovu	J0179	Medical Drug Management	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Cabotegravir and Rilpivirine	Cabenuva	J0741	Medical Drug Management	Anti-Infective Agents	Y	
Cabotegravir extended-release injectable suspension	Apretude	J0739	Medical Drug Management	Anti-Infective Agents	Y	
Canakinumab	Ilaris	J0638	Medical Drug Management	Analgesics and Anesthetics	Y	
Caplacizumab-yhdp	Cablivi	C9047	Medical Drug Management	Hematological Agents	Y	
Caplacizumab-yhdp	Cablivi	J3590	Medical Drug Management	Hematological Agents	Y	
Cipaglucosidase alfa-atga	Pombiliti	J1203	Medical Drug Management	Treatment of late-onset Pompe disease	Y	New permanent HCPC Code: J1203 will replace NOC Codes: C9399 & J3590 for Pombiliti, effective: 04/01/24
Cipaglucosidase alfa-atga	Pombiliti	C9399	Medical Drug Management	Treatment of late-onset Pompe disease	Y	New permanent HCPC Code: J1203 will replace NOC Codes: C9399 & J3590 for Pombiliti, effective: 04/01/24
Cipaglucosidase alfa-atga	Pombiliti	J3590	Medical Drug Management	Treatment of late-onset Pompe disease	Y	New permanent HCPC Code: J1203 will replace NOC Codes: C9399 & J3590 for Pombiliti, effective: 04/01/24
Coagulation Factor X (Human)	Coagadex	J7175	Medical Drug Management	Hematological Agents	Y	
Coagulation Factor XIII A-Subunit (Recombinant)	Tretten	J7181	Medical Drug Management	Hematological Agents	Y	
Crizanlizumab-tmca	Adakveo	J0791	Medical Drug Management	Hematological Agents	Y	
Darbepoetin Alfa	Aranesp, Aranesp for NON-ESRD	J0881	Medical Drug Management	Hematological Agents	Y	
DaxibotulinumtoxinA-lanm	Daxxify	J0589	Medical Drug Management	Topical Products	Y	New permanent HCPC Code: J0589 will replace NOC Codes: C9160 & J3590 for Daxxify, effective: 04/01/24
DaxibotulinumtoxinA-lanm	Daxxify	C9160	Medical Drug Management	Topical Products	Y	New permanent HCPC Code: J0589 will replace NOC Codes: C9160 & J3590 for Daxxify, effective: 04/01/24

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
DaxibotulinumtoxinA-lanm	Daxxify	J3590	Medical Drug Management	Topical Products	Y	New permanent HCPC Code: J0589 will replace NOC Codes: C9160 & J3590 for Daxxify, effective: 04/01/24
Denosumab	Prolia	J0897	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Eculizumab	Soliris	J1300	Medical Drug Management	Hematological Agents	Y	
Edaravone	Radicava	J1301	Medical Drug Management	Neuromusclar Drugs	Y	
Efgartigimod alfa-fcab	Vyvgart	J9332	Medical Drug Management	Miscellaneous Products	Y	
Efgartigimod alfa-fcab & Hyaluronidase-qvfc	Vyvgart Hytrulo	J9334	Medical Drug Management	Miscellaneous Products	Y	
Elapegademase-lvlr	Revcovi	C9399	Medical Drug Management	ADA-SCID	Y	
Elapegademase-lvlr	Revcovi	J3590	Medical Drug Management	ADA-SCID	Y	
Elosulfase Alfa	Vimizim	J1322	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Emicizumab-kxwh	Hemlibra	J7170	Medical Drug Management	Hematological Agents	Y	
Epoetin Alfa	Epogen, Procrit	J0885	Medical Drug Management	Hematological Agents	Y	
Epoetin alfa - epbx	Retacrit	Q5106	Medical Drug Management	Hematological Agents	Y	
Epoprostenol	Epoprostenol, Flolan, Veletri	J1325	Medical Drug Management	Cardiovascular Agents	Y	
Eptinezumab-jjmr (Vyepi)	Vyepi	J3032	Medical Drug Management	Analgesics and Anesthetics	Y	
Esketamine	Spravato	S0013	Medical Drug Management	Central Nervous Systems Drugs	Y	
Etelcalcetide Injection	Parsabiv	J0606	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Evinacumab-dgnb	Evkeeza	J1305	Medical Drug Management	Cardiovascular Agents	Y	
Factor IX (albumin fusion protein, recombinant)	Idelvion	J7202	Medical Drug Management	Hematological Agents	Y	
Factor IX (antihemophilic factor, purified, non-recombinant)	AlphaNine SD, Mononine	J7193	Medical Drug Management	Hematological Agents	Y	
Factor IX (antihemophilic factor, recombinant)	Ixinity	J7213	Medical Drug Management	Hematological Agents	Y	
Factor IX (antihemophilic factor, recombinant)	BeneFix, Ixinity	J7195	Medical Drug Management	Hematological Agents	Y	
Factor IX (antihemophilic factor, recombinant)	Rixubis	J7200	Medical Drug Management	Hematological Agents	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Factor IX (antihemophilic factor, recombinant), glycopegylated	Rebinyn	J7203	Medical Drug Management	Hematological Agents	Y	
Factor IX (Fc fusion protein, recombinant)	Alprolix	J7201	Medical Drug Management	Hematological Agents	Y	
Factor IX Complex	Bebulin, Profilnine/Profilnine SD	J7194	Medical Drug Management	Hematological Agents	Y	
Factor viia (antihemophilic factor, recombinant)-jncw	Sevenfact	J7212	Medical Drug Management	Hematological Agents	Y	
Factor VIII (antihemophilic factor, human)	Koate/Koate-DVI, Hemofil M	J7190	Medical Drug Management	Hematological Agents	Y	
Factor VIII (antihemophilic factor, recombinant)	Afstyla	J7210	Medical Drug Management	Hematological Agents	Y	
Factor VIII (antihemophilic factor, recombinant)	Kovaltry	J7211	Medical Drug Management	Hematological Agents	Y	
Factor VIII (antihemophilic factor, recombinant)	Nuwiq	J7209	Medical Drug Management	Hematological Agents	Y	
Factor VIII (antihemophilic factor, recombinant), pegylated	Adynovate	J7207	Medical Drug Management	Hematological Agents	Y	
Factor VIII (antihemophilic factor, recombinant), pegylated-aucl	Jivi	J7208	Medical Drug Management	Hematological Agents	Y	
Factor VIII (antihemophilic Factor, Recombinant)	Novoeight	J7182	Medical Drug Management	Hematological Agents	Y	
Factor VIII (antihemophilic Factor, Recombinant)	Xyntha	J7185	Medical Drug Management	Hematological Agents	Y	
Factor VIII (antihemophilic Factor, Recombinant)	Advate, Kogenate FS, Recombinate	J7192	Medical Drug Management	Hematological Agents	Y	
Factor VIII (Fc fusion protein, recombinant)	Eloctate	J7205	Medical Drug Management	Hematological Agents	Y	
Factor VIII / VON Willebrand Factor Complex, Recombinant	Altuviiio per factor viii iu	J7214	Medical Drug Management	Hematological Agents	Y	
Factor XIII Concentrate (antihemophilic factor, human)	Corifact	J7180	Medical Drug Management	Hematological Agents	Y	
Factore VIIA (antihemophilic factor, recombinant)	NovoSeven-RT	J7189	Medical Drug Management	Hematological Agents	Y	
Faricimab-svoa	Vabysmo	J2777	Medical Drug Management	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Fecal Microbiota, Live-jsl	Rebyota	J1440	Medical Drug Management	Gastrointestinal Agents	Y	
Ferric Carboxymaltose	Injectafer	J1439	Medical Drug Management	Hematological Agents	Y	
Ferric Derisomaltose	Monoferric	J1437	Medical Drug Management	Hematological Agents	Y	
Ferumoxytol	Feraheme	Q0138	Medical Drug Management	Hematological Agents	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Fibrinogen (Human)	RiaSTAP	J7178	Medical Drug Managment	Hematological Agents	Y	
Filgrastim	Neupogen	J1442	Medical Drug Managment	Hematological Agents	Y	
Filgrastim-aafi	Nivestym	Q5110	Medical Drug Managment	Hematological Agents	Y	
Filgrastim-ayow	Releuko	Q5125	Medical Drug Managment	Hematological Agents	Y	
Filgrastim-sndz	Zarxio	Q5101	Medical Drug Managment	Hematological Agents	Y	
Fosdenopterin	Nulibry	C9399	Medical Drug Managment	Molybdenum Cofactor Deficiency	Y	
Fosdenopterin	Nulibry	J3490	Medical Drug Managment	Molybdenum Cofactor Deficiency	Y	
Galsulfase	Naglazyme	J1458	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Givosiran	Givlaari	J0223	Medical Drug Managment	Hematological Agents	Y	
Golimumab	Simponi Aria	J1602	Medical Drug Managment	Analgesics and Anesthetics	Y	
Human fibrinogen concentrate	Fibryga	J7177	Medical Drug Managment	Hematological Agents	Y	
Ibalizumab-uryk	Trogarzo	J1746	Medical Drug Managment	Anti-Infective Agents	Y	
Ibandronate sodium	Boniva	J1740	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Idursulfase	Elaprase	J1743	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Imiglucerase	Cerezyme	J1786	Medical Drug Managment	Hematological Agents	Y	
Immune Globulin	Panzyga	J1576	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Cuvitru	J1555	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Hyqvia	J1575	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Bivigam	J1556	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Gamunex-C, Gammaked	J1561	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Gammagard liquid	J1569	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Gammaplex	J1557	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Hizentra	J1559	Medical Drug Managment	Biologicals	Y	
Immune Globulin	Panzyga, Immune Globulin (not otherwise specified)	J1599	Medical Drug Managment	Biologicals	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Immune Globulin	Privigen	J1459	Medical Drug Management	Biologicals	Y	
Immune Globulin	Flebogamma DIF	J1572	Medical Drug Management	Biologicals	Y	
Immune Globulin	Cuvitru, Cutaquig, Gammagard, Gammaked, Gamunex-C, Hizentra, Xembify	90284	Medical Drug Management	Biologicals	Y	
Immune Globulin	Carimune NF, Gammagard S/D, Panglobulin NF	J1566	Medical Drug Management	Biologicals	Y	
Immune Globulin	Octagam	J1568	Medical Drug Management	Biologicals	Y	
Immune Globulin	Gammagard, Asceniv, Panzyga, Bivigam, Flebogamma, Gammaked, Gamunex-C, Gammplex, Octagam, Privigen	90283	Medical Drug Management	Biologicals	Y	
Immune Globulin intravenous, human - sira	Asceniv	J1554	Medical Drug Management	Biologicals	Y	
Immune Globulin intravenous, human - sira	Asceniv	J1599	Medical Drug Management	Biologicals	Y	
Immune Globulin Subcutaneous, human - klhw	Xembify	J1558	Medical Drug Management	Biologicals	Y	
Immune Globulin Subcutaneous	Cutaquig	J1551	Medical Drug Management	Biologicals	Y	
Inclisiran	Leqvio	J1306	Medical Drug Management	Cardiovascular Agents	Y	
IncobotulinumtoxinA	Xeomin	J0588	Medical Drug Management	Neuromusclar Drugs	Y	
Inebilizumab-cdon	Uplizna	J1823	Medical Drug Management	Miscellaneous Products	Y	
Infliximab	Inflectra	Q5103	Medical Drug Management	Gastrointestinal Agents	Y	
Infliximab	Remicade	J1745	Medical Drug Management	Gastrointestinal Agents	Y	
Infliximab-abda	Renflexis	Q5104	Medical Drug Management	Gastrointestinal Agents	Y	
Infliximab-axxq	Avsola	Q5121	Medical Drug Management	Gastrointestinal Agents	Y	
Injection, romosozumab-aqqg, 1 mg	Evenity	J3111	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Interferon Gamma-1 b	Actimmune	J9216	Medical Drug Management	Antineoplastic Agents and Adjunctive Therapies	Y	
Intra-Articular Hyaluronan Injections	Sodium hyaluronate 1%	C9399	Medical Drug Management	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Sodium hyaluronate 1%	J3490	Medical Drug Management	Neuromusclar Drugs	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Intra-Articular Hyaluronan Injections	Synjoynt	J7331	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Triluron	J7332	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Durolane	J7318	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	TriVisc	J7329	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Genvisc 850	J7320	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Hymovis	J7322	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Gelsyn-3	J7328	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Monovisc	J7327	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Gel-One	J7326	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Synvisc, Synvisc-One	J7325	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Hyalgan, Supartz, Supartz FX, (Visco-3 as of 4/1/21)	J7321	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Euflexxa	J7323	Medical Drug Managment	Neuromusclar Drugs	Y	
Intra-Articular Hyaluronan Injections	Orthovisc	J7324	Medical Drug Managment	Neuromusclar Drugs	Y	
Lanreotide	Somatuline	J1930	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Lanreotide (Cipla)		J1932	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Laronidase	Aldurazyme	J1931	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Lenacapavir Injenction	Sunlenca Injection	J1961	Medical Drug Managment	Anti-Infective Agents	Y	
Leuprolide acetate	Fensolvi	J1951	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Leuprolide acetate	Lupron	J1950	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Lumasiran	Oxlumo	J0224	Medical Drug Managment	Genitourinary Products	Y	
Luspatercept-aamt	Reblozyl	J0896	Medical Drug Managment	Hematological Agents	Y	
Mepolizumab	Nucala	J2182	Medical Drug Managment	Respiratory Agents	Y	
Methoxy Polyethylene Glycol-Epoetin Beta	Mircera, Mircera for NON-ESRD	J0888	Medical Drug Managment	Hematological Agents	Y	
Natalizumab	Tysabri	J2323	Medical Drug Managment	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	



Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Nusinersen	Spinraza	J2326	Medical Drug Management	Neuromuscular Drugs	Y	
Ocrelizumab	Ocrevus	J2350	Medical Drug Management	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Octreotide	Sandostatin LAR	J2353	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Octreotide	Sandostatin	J2354	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Olipudase alfa-rpcp	Xenpozyme	J0218	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Omalizumab	Xolair	J2357	Medical Drug Management	Respiratory Agents	Y	
OnabotulinumtoxinA	Botox	J0585	Medical Drug Management	Neuromuscular Drugs	Y	
Palivizumab	Synagis	90378	Medical Drug Management	Biologicals	Y	
Pasireotide	Signifor LAR	J2502	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Patisiran	Onpattro	J0222	Medical Drug Management	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Pegcetaplan	Syfovre	J2781	Medical Drug Management	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Pegunigalsidase alfa-iwxj	Elfabrio	J2508	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Plasminogen, human-tvmh	Ryplazim	J2998	Medical Drug Management	Hematological Agents	Y	
Pozelimab-bbfg	Veopoz	J9376	Medical Drug Management	Treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease	Y	New Permanent HCPC Code: J9376 will replace NOC Code: C9399 & J3590 for Veopoz, effective: 04/01/24
Pozelimab-bbfg	Veopoz	C9399	Medical Drug Management	Treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease	Y	New Permanent HCPC Code: J9376 will replace NOC Code: C9399 & J3590 for Veopoz, effective: 04/01/24
Pozelimab-bbfg	Veopoz	J3590	Medical Drug Management	Treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease	Y	New Permanent HCPC Code: J9376 will replace NOC Code: C9399 & J3590 for Veopoz, effective: 04/01/24
Ranibizumab	Susvimo	J2779	Medical Drug Management	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Ranibizumab	Lucentis	J2778	Medical Drug Management	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Ranibizumab-eqrn	Cimerli	Q5128	Medical Drug Management	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Ranibizumab-nuna	Byooviz	Q5124	Medical Drug Management	Dermatological/Anorectal /Mouth-Throat/Dental/Ophthalmic/Otic	Y	
Ravulizumab-cwvz	Ultomiris	J1303	Medical Drug Management	Hematological Agents	Y	
Remdesivir	Veklury	J0248	Medical Drug Management	Anti-Infective Agents	Y	
Reslizumab	Cinqair	J2786	Medical Drug Management	Respiratory Agents	Y	
Riloncept	Arcalyst	J2793	Medical Drug Management	Analgesics and Anesthetics	Y	
RimabotulinumtoxinB	Myobloc	J0587	Medical Drug Management	Neuromusclar Drugs	Y	
Rituximab	Rituxan	J9312	Medical Drug Management	Antineoplastic Agents and Adjunctive Therapies	Y	
Rituximab-abbs (Truxima)	Truxima	Q5115	Medical Drug Management	Antineoplastic Agents and Adjunctive Therapies	Y	
Rituximab-arrx	Riabni	Q5123	Medical Drug Management	Antineoplastic Agents and Adjunctive Therapies	Y	
Rituximab-pvvr	Ruxience	Q5119	Medical Drug Management	Antineoplastic Agents and Adjunctive Therapies	Y	
Romiplostim	Nplate	J2796	Medical Drug Management	Hematological Agents	Y	
Rozanolixizumab-noli	Rystiggo	J9333	Medical Drug Management	Miscellaneous Products	Y	
Sebelipase alfa	Kanuma	J2840	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Spesolimab-sbzo	Spevigo	J1747	Medical Drug Management	Topical Products	Y	
Sutimlimab-jome	Enjaymo	J1302	Medical Drug Management	Hematological Agents	Y	
Taliglucerase Alfa	Elelyso	J3060	Medical Drug Management	Endocrine and Metabolic Drugs	Y	
Teplizumab-mzww	Tzield	J9381	Medical Drug Management	Endocrine and Metabolic Drugs	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Teprotumumab-trbw	Tepezza	J3241	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Tezepelumab-ekko	Tezspire	J2356	Medical Drug Managment	Respiratory Agents	Y	
Tildrakizumab-asmn	Ilumya	J3245	Medical Drug Managment	Topical Products	Y	
Tocilizumab-bavi	Tofidence	C9399	Medical Drug Managment	<p>For the Treatment of:</p> <p>1) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)</p> <p>2) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.</p> <p>3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.</p>	Y	
Tocilizumab-bavi	Tofidence	J3490	Medical Drug Managment	<p>For the Treatment of:</p> <p>1) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)</p> <p>2) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.</p> <p>3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.</p>	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Tocilizumab-bavi	Tofidence	J3590	Medical Drug Managment	For the Treatment of: 1) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 2) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. 3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.	Y	
Tocilizumab-bavi	Tofidence	J9999	Medical Drug Managment	For the Treatment of: 1) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 2) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. 3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.	Y	
Tofersen	Qalsody	J1304	Medical Drug Managment	Neuromusclar Drugs	Y	
Treprostinil	Remodulin	J3285	Medical Drug Managment	Cardiovascular Agents	Y	
Triamcinolone ER	Zilretta	J3304	Medical Drug Managment	Endocrine and Metabolic Agents	Y	

Effective Date: 04/01/2024

Description	Alt Descriptions	Procedure Code	Program	Therapeutic Drug Category	BCBSAZ - Commercial	Drug Comments
Ublituximab-xiiy	Briumvi	J2329	Medical Drug Managment	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Velaglucerase Alfa	Vpriv	J3385	Medical Drug Managment	Hematological Agents	Y	
Velmanase alfa-tycv	Lamzede	J0217	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
Vestronidase alfa-vjbk	Mepsevii	J3397	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	
von Willebrand Factor (Recombinant)	Vonvendi	J7179	Medical Drug Managment	Hematological Agents	Y	
von Willebrand Factor complex	Humate-P	J7187	Medical Drug Managment	Hematological Agents	Y	
von Willebrand Factor complex (human)	Wilate	J7183	Medical Drug Managment	Hematological Agents	Y	
von Willebrand Factor complex (human)	Alphanate	J7186	Medical Drug Managment	Hematological Agents	Y	
Vutrusiran	Amvuttra	J0225	Medical Drug Managment	Psychotherapeutic and Neurological Agents - Miscellaneous	Y	
Zoledronic Acid	Reclast	J3489	Medical Drug Managment	Endocrine and Metabolic Drugs	Y	